AB Science reports operating deficit, positive results in Covid-19 study, ongoing EMA re-examination

From GlobeNewswire: 2024-10-10 02:28:00

AB Science presents its financial results for the first half of 2024, with an operating deficit of 3.6 million euros and a cash position of 9.1 million euros. Key events include ongoing re-examination by EMA and Health Canada for masitinib in ALS, positive results in a phase 2 study of masitinib in Covid-19, and updates on the AB8939 microtubule program. AB Science requested a re-examination of the EMA’s negative opinion on the marketing authorization application for masitinib in ALS, citing the urgent need for patients to access treatment and acceptable safety data. The re-examination is ongoing by EMA. In Canada, Health Canada issued a Notice of Deficiency-Withdrawal for masitinib in ALS, and AB Science has submitted a reconsideration request. The update on the AB8939 microtubule program highlights its ability to generate a response on MECOM rearrangement, showing promise in AML treatment. Additionally, progress continues in developing masitinib for progressive forms of multiple sclerosis following the ECTRIMS 2024 conference.



Read more at GlobeNewswire:: Revenues for the first half of 2024 and update